Researcher Graphically Illustrating Which Treatments Are Best for Prostate Cancer

VBCC - May 2010, Volume 1, No 1 - Genitourinary Cancers Symposium
Rosemary Frei, MSc

San Francisco, CA—The expression “a picture is worth a thousand words” is certainly true when it comes to figures from a new literature review of prostate cancer (PCa) treatments.

In a presentation at the American Society of Clinical Oncology’s 2010 Genitourinary Cancers Symposium, Peter Grimm, DO, showed that brachytherapy is more effective than surgery or electron beam radiation therapy (EBRT) in preventing progression in low- and intermediate-risk PCa.

Dr Grimm, executive director of the Prostate Cancer Treatment Center, Seattle, Wash, helped put together a panel of 25 radiation oncologists, brachytherapists, urologists, and medical oncologists from North America and Europe. They developed and then applied a set of strict inclusion criteria to 603 PCa treatment-related articles published since 2000. Dr Grimm then marked on graphs the rate of progression-free survival from each of the 51 articles that met all the criteria.

The results show that, for most patients with low- or intermediate-risk PCa, brachytherapy provides better outcomes than either surgery or EBRT.

The average prostate-specific antigen (PSA) progression-free survival rate from the low-risk PCa studies was 98% for brachytherapy, 92% for surgery, and 80% for EBRT.

Moreover, this sequence of effectiveness remained when Dr Grimm widened the inclusion criteria to take in low-risk PCa studies that had a median follow-up of ≥40 months or enrolled <100 patients, and when he examined intermediate-risk PCa (Figure). “PCRSG” stands for Prostate Cancer Results Study Group, which is the 25-member panel. Each symbol indicates an individual study; the shapes of the symbols represent the types of treatments, and the large circles represent the range of results from all of the studies of each treatment modality. (A full list of the studies referenced in this figure is available from the author—contact This email address is being protected from spambots. You need JavaScript enabled to view it..)

“Dr Grimm’s work synthesizes and summarizes the best retrospective data available regarding the relative strengths and weaknesses of all the available treatment options for prostate cancer…he did not ‘cherry pick’ articles from the literature,” commented Mark Scholz, MD, medical director, Prostate Oncology Specialists, Marina del Ray, Calif, and clinical assistant professor, Department of Medical Oncology, University of Southern California, Los Angeles. “It is a significant accomplishment, because there presently are no prospective comparisons and nor are there likely to be any in the future.”

The PCRSG criteria were:

  • patients stratified into pretreatment, low-, intermediate- or high-risk groups, according to the D’Amico, Zelefsky, or National Comprehensive Cancer Network criteria;
  • biochemical relapse-free survival used as the standard end point—defined based on either the American Society of Therapeutic Radiology and Oncology or the Phoenix criteria, and including PSA <0.2 ng/mL;
  • no postsurgery pathological staging—clinical staging only;
  • EBRT with ≥72 Gy, including intensity modulated radiation therapy and conformal radiation therapy;
  • published in a peer-reviewed journal;
  • ≥100 patients if focused on low- or intermediate-risk disease;
  • ≥50 patients if focused on high-risk disease; and,
  • minimum median follow-up of 5 years.

Only 13% of the brachytherapy articles, 7% of the radical prostatectomy articles, and 0% of the high-intensity–focused ultrasound articles met all of these criteria.

Dr Grimm has not yet completed the analyses for the high-risk PCa studies.

“What I hope this kind of data does is also highlight the lack of uniformity of reporting,” concluded Dr Grimm. “We hope to move the field towards journal editors saying, ‘If you want your studies to be comparable to other work in the literature, they will have to meet these basic criteria.”

Related Items
Poor Pregnancy Outcomes Seen in Women with Childhood-Onset SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 23, 2016 in Canadian Rheumatology Association Annual Meeting
Addressing Undertreatment of Patients with Gout Using EMR Data
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 11, 2016 in Canadian Rheumatology Association Annual Meeting
Six-Month OBSErve Study Results Indicate Positive Effects of Belimumab in SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 8, 2016 in Canadian Rheumatology Association Annual Meeting
Improvements Needed in Access to Timely Quality Care
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 7, 2016 in Canadian Rheumatology Association Annual Meeting
Orthotics Reduce Foot Pain in Juvenile Idiopathic Arthritis
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 4, 2016 in Juvenile Idiopathic Arthritis
Biosimilar Infliximab Recommended for Approval
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in FDA Approvals, News & Updates
Early Response to Abatacept Detectable by Sophisticated Ultrasound
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Rheumatoid Arthritis
Updated Recommendations for Pharmacologic Treatment of Patients with Psoriatic Arthritis
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Psoriatic Arthritis
Two Studies Point to Inadequate Evidence Supporting Many FDA Drug Approvals
Rosemary Frei, MSc
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Health Policy
Multidisciplinary Approach or Aerobic Exercise for Fibromyalgia May Not Be Cost-Effective
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Fibromyalgia
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology